iBio, Inc. (IBIO)
Company Description
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.
It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.
iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever.
The company was incorporated in 2008 and is headquartered in Bryan, Texas.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 26 |
CEO | Dr. Martin B. Brenner D.V.M., Ph.D. |
Contact Details
Address: 600 Madison Avenue, Suite 1601 New York, New York 10022-1737 United States | |
Phone | 302 355-0650 |
Website | ibioinc.com |
Stock Details
Ticker Symbol | IBIO |
Exchange | NYSEAMERICAN |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001420720 |
CUSIP Number | 451033203 |
ISIN Number | US4510337086 |
Employer ID | 26-2797813 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Martin B. Brenner D.V.M., Ph.D. | Chief Executive Officer and Chief Scientific Officer |
Felipe Duran | Chief Financial Officer |
Stephen Kilmer | Investor Relations Officer |
Marc Banjak J.D. | General Counsel |
Robert B. Kay | Interim Secretary and Interim Treasurer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 26, 2024 | 8-K | Current Report |
Feb 21, 2024 | 8-K | Current Report |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | 10-Q | Quarterly Report |
Jan 19, 2024 | 8-K | Current Report |
Jan 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Jan 8, 2024 | 8-K | Current Report |
Jan 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Dec 26, 2023 | 8-K | Current Report |
Dec 8, 2023 | 8-K | Current Report |